These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3829513)

  • 1. [Short-term treatment of progressive supranuclear palsy with amitriptyline].
    Yamashi M; Sanada J; Miyazaki Y; Ikeda H
    Rinsho Shinkeigaku; 1986 Nov; 26(11):1138-41. PubMed ID: 3829513
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of progressive supranuclear palsy showing marked improvements of frontal hypoperfusion, as well as parkinsonism with amitriptyline].
    Asanuma M; Hirata H; Kondo Y; Ogawa N
    Rinsho Shinkeigaku; 1993 Mar; 33(3):317-21. PubMed ID: 8334795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.
    Rascol O; Sieradzan K; Peyro-Saint-Paul H; Thalamas C; Brefel-Courbon C; Senard JM; Ladure P; Montastruc JL; Lees A
    Mov Disord; 1998 Jul; 13(4):673-6. PubMed ID: 9686773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy.
    Polo KB; Jabbari B
    Ann Neurol; 1994 Feb; 35(2):237-9. PubMed ID: 8109906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects.
    Engel PA
    J Am Geriatr Soc; 1996 Sep; 44(9):1072-4. PubMed ID: 8790233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Improvement of ophthalmoplegia by 5-hydroxytryptophan in two cases of progressive supranuclear palsy].
    Yukitake M; Takashima Y; Kurohara K; Matsui M; Kuroda Y
    Rinsho Shinkeigaku; 1996 Jul; 36(7):906-8. PubMed ID: 8952364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zolpidem in progressive supranuclear palsy.
    Daniele A; Moro E; Bentivoglio AR
    N Engl J Med; 1999 Aug; 341(7):543-4. PubMed ID: 10447452
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective study of drug response in 87 patients with progressive supranuclear palsy.
    Nieforth KA; Golbe LI
    Clin Neuropharmacol; 1993 Aug; 16(4):338-46. PubMed ID: 8374914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.
    Kim JM; Lee KH; Choi YL; Choe GY; Jeon BS
    Mov Disord; 2002 Sep; 17(5):1089-90. PubMed ID: 12360566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progressive supranuclear palsy: neurological, neuropathological and neuropsychological aspects].
    Gómez-Haro C; Espert-Tortajada R; Gadea-Doménech M; Navarro-Humanes JF
    Rev Neurol; 1999 Nov 16-30; 29(10):936-56. PubMed ID: 10637844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of progressive supranuclear palsy showing improvement of rigidity, nuchal dystonia and autonomic failure with trazodone].
    Kato E; Takahashi S; Abe T; Kawamorita A; Tohgi H
    Rinsho Shinkeigaku; 1994 Oct; 34(10):1013-7. PubMed ID: 7834944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T
    Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Descriptive study of a serie of patients affected by progressive supranuclear palsy].
    Villanueva-Haba VE; Garcés M; de Vera A; Valero C; Burguera JA
    Rev Neurol; 2001 Jun 1-15; 32(11):1027-30. PubMed ID: 11562823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive dopamine neuron loss in progressive supranuclear palsy.
    Murphy KE; Karaconji T; Hardman CD; Halliday GM
    Mov Disord; 2008 Mar; 23(4):607-10. PubMed ID: 18163454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.
    Poorkaj P; Muma NA; Zhukareva V; Cochran EJ; Shannon KM; Hurtig H; Koller WC; Bird TD; Trojanowski JQ; Lee VM; Schellenberg GD
    Ann Neurol; 2002 Oct; 52(4):511-6. PubMed ID: 12325083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autonomic dysfunction in patients with progressive supranuclear palsy.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Reichmann H; Berg D; Ziemssen T
    Mov Disord; 2008 Oct; 23(14):2083-9. PubMed ID: 18792126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repetitive transcranial magnetic stimulation in patients with progressive supranuclear palsy: a pilot study.
    Santens P; Sieben A; De Letter M
    Acta Neurol Belg; 2009 Sep; 109(3):200-4. PubMed ID: 19902813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.